Purpose: To assess and describe sequential morphological changes in the choroidal neovascularization (CNV) net using optical coherence tomography angiography (OCTA) in patients undergoing treatment with intravitreal antivascular endothelial growth factor (VEGF). Methods: Prospective cohort study. OCTA was performed sequentially: before (t0), 1 h (t1), 1 week (t2) and 1 month after the injection (t3), using Avanti RTVue XR equipped with the AngioVue® software (Optovue, Calif., USA). All images were classified by two independent graders. Results: Ten eyes of 10 patients, with a mean age of 72.4 ± 10.5 years, were included. CNV morphology was described as tree-like in 5 eyes, glomerular in 1 and fragmented in 4. A fibrovascular capsule surrounding the CNV net was found in 4 eyes and a feeder trunk was noticed in 6. No changes were observed at t1. Loss of peripheral capillaries, vessel fragmentation and decreased vessel density were evident in 8 eyes at t2. The CNV capillary density and the peripheral anastomosis increased in all of these at t3. Two eyes remained unchanged through the whole length of follow-up. Conclusions: Significant changes in the CNV net can be observable in OCTA at least 1 week after intravitreal anti-VEGF. The safety of frequent examinations may provide a method of gauging treatment effects.

Keywords:
Age-related macular degeneration, Antivascular endothelial growth factor, Choroidal neovascularization , Imaging, Optical coherence tomography angiography, Image analysis
1.
Cachulo M da L, Lobo C, Figueira J, Ribeiro L, Lains I, Vieira A, Nunes S, Costa M, Simao S, Rodrigues V, et al: Prevalence of age-related macular degeneration in Portugal: the Coimbra Eye Study - report 1. Ophthalmologica 2015;233:119-127.
2.
Tomany SC, Wang JJ, Van Leeuwen R, Klein R, Mitchell P, Vingerling JR, Klein BE, Smith W, De Jong PT: Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology 2004;111:1280-1287.
3.
Sulzbacher F, Kiss C, Munk M, Deak G, Sacu S, Schmidt-Erfurth U: Diagnostic evaluation of type 2 (classic) choroidal neovascularization: optical coherence tomography, indocyanine green angiography, and fluorescein angiography. Am J Ophthalmol 2011;152:799-806.
4.
Spaide RF: Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization. Am J Ophthalmol 2015;160:6-16.
5.
Su Z, Ye P, Teng Y, Zhang L, Shu X: Adverse reaction in patients with drug allergy history after simultaneous intravenous fundus fluorescein angiography and indocyanine green angiography. J Ocul Pharmacol Ther 2012;28:410-413.
6.
Lipson BK, Yannuzzi LA: Complications of intravenous fluorescein injections. Int Ophthalmol Clin 1989;29:200-205.
7.
Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, et al: Optical coherence tomography. Science 1991;254:1178-1181.
8.
Swanson EA, Izatt JA, Hee MR, Huang D, Lin CP, Schuman JS, Puliafito CA, Fujimoto JG: In vivo retinal imaging by optical coherence tomography. Optics Lett 1993;18:1864-1866.
9.
De Carlo TE, Bonini Filho MA, Chin AT, Adhi M, Ferrara D, Baumal CR, Witkin AJ, Reichel E, Duker JS, Waheed NK: Spectral-domain optical coherence tomography angiography of choroidal neovascularization. Ophthalmology 2015;122:1228-1238.
10.
Moult E, Choi W, Waheed NK, Adhi M, Lee B, Lu CD, Jayaraman V, Potsaid B, Rosenfeld PJ, Duker JS, et al: Ultrahigh-speed swept-source OCT angiography in exudative AMD. Ophthalmic Surg Lasers Imaging Retina 2014;45:496-505.
11.
Lumbroso B, Huang D, Jia Y, Fujimoto JG, Rispoli M: Clinical Guide to Angio-OCT: Non-Invasive, Dyeless OCT Angiography, ed 1. New Delhi, Jaypee Brothers Medical Publishers, 2015.
12.
Savastano MC, Lumbroso B, Rispoli M: In vivo characterization of retinal vascularization morphology using optical coherence tomography angiography. Retina 2015;35:2196-2203.
13.
Jia Y, Tan O, Tokayer J, Potsaid B, Wang Y, Liu JJ, Kraus MF, Subhash H, Fujimoto JG, Hornegger J, et al: Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Optics Express 2012;20:4710-4725.
14.
Tokayer J, Jia Y, Dhalla AH, Huang D: Blood flow velocity quantification using split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Biomed Optics Express 2013;4:1909-1924.
15.
Puliafito CA: OCT angiography: the next era of OCT technology emerges. Ophthalmic Surg Lasers Imaging Retina 2014;45:360.
16.
Jia Y, Bailey ST, Wilson DJ, Tan O, Klein ML, Flaxel CJ, Potsaid B, Liu JJ, Lu CD, Kraus MF, et al: Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology 2014;121:1435-1444.
17.
Kuehlewein L, Sadda SR, Sarraf D: OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy. Eye 2015;29:932-935.
18.
Coscas GJ, Lupidi M, Coscas F, Cagini C, Souied EH: Optical coherence tomography angiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: a new diagnostic challenge. Retina 2015;35:2219-2228.
19.
Lumbroso B, Rispoli M, Savastano MC: Longitudinal optical coherence tomography-angiography study of type 2 naive choroidal neovascularization early response after treatment. Retina 2015;35:2242-2251.
20.
Huang D, Jia Y, Rispoli M, Tan O, Lumbroso B: Optical coherence tomography angiography of time course of choroidal neovascularization in response to anti-angiogenic treatment. Retina 2015;35:2260-2264.
21.
Kuehlewein L, Bansal M, Lenis TL, Iafe NA, Sadda SR, Bonini Filho MA, De Carlo TE, Waheed NK, Duker JS, Sarraf D: Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration. Am J Ophthalmol 2015;160:739-748.
22.
Spaide RF, Klancnik JM Jr, Cooney MJ: Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol 2015;133:45-50.
23.
Coscas G, Lupidi M, Coscas F, Francais C, Cagini C, Souied EH: Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy. Ophthalmic Res 2015;54:57-63.
24.
Muakkassa NW, Chin AT, de Carlo T, Klein KA, Baumal CR, Witkin AJ, Duker JS, Waheed NK: Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina 2015;35:2252-2259.
25.
Bellou S, Pentheroudakis G, Murphy C, Fotsis T: Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett 2013;338:219-228.
26.
Schierling W, Troidl K, Troidl C, Schmitz-Rixen T, Schaper W, Eitenmuller IK: The role of angiogenic growth factors in arteriogenesis. J Vasc Res 2009;46:365-374.
27.
Querques G, Capuano V, Frascio P, Bandello F, Souied EH: Emerging therapeutic options in age-related macular degeneration. Ophthalmic Research 2015;53:194-199.
28.
Ishikawa M, Jin D, Sawada Y, Abe S, Yoshitomi T: Future therapies of wet age-related macular degeneration. J Ophthalmol 2015;2015:138070.
29.
Muether PS, Hermann MM, Droge K, Kirchhof B, Fauser S: Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol 2013;156:989-993.
30.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
31.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ: Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-2182.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.